Research Analysts Offer Predictions for RNTX Q2 Earnings

Rein Therapeutics Inc. (NASDAQ:RNTX) – Equities research analysts at HC Wainwright increased their Q2 2026 EPS estimates for Rein Therapeutics in a research note issued to investors on Monday, June 1st. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings per share of ($0.27) for the quarter, up from their previous forecast of ($0.49). HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Rein Therapeutics’ current full-year earnings is ($1.63) per share. HC Wainwright also issued estimates for Rein Therapeutics’ Q3 2026 earnings at ($0.10) EPS, Q4 2026 earnings at ($0.13) EPS, FY2026 earnings at ($0.53) EPS, FY2027 earnings at ($0.50) EPS, FY2028 earnings at ($0.66) EPS and FY2029 earnings at ($0.57) EPS.

Rein Therapeutics (NASDAQ:RNTX) last posted its earnings results on Friday, May 15th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.30.

Separately, Wall Street Zen upgraded Rein Therapeutics to a “sell” rating in a research report on Saturday, May 16th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $7.00.

Rein Therapeutics Trading Down 3.7%

NASDAQ:RNTX opened at $1.03 on Wednesday. The stock has a 50 day simple moving average of $1.32 and a 200 day simple moving average of $1.30. The stock has a market cap of $88.11 million, a P/E ratio of -0.54 and a beta of 1.35. Rein Therapeutics has a 1-year low of $0.95 and a 1-year high of $2.18.

Hedge Funds Weigh In On Rein Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC bought a new stake in shares of Rein Therapeutics during the 2nd quarter valued at $344,000. Northwestern Mutual Wealth Management Co. bought a new position in shares of Rein Therapeutics in the second quarter worth $68,000. Cable Car Capital LP bought a new position in shares of Rein Therapeutics in the second quarter worth $588,000. Vanguard Group Inc. raised its stake in Rein Therapeutics by 32.2% in the third quarter. Vanguard Group Inc. now owns 1,168,407 shares of the company’s stock valued at $1,338,000 after purchasing an additional 284,300 shares in the last quarter. Finally, Prosight Management LP raised its stake in Rein Therapeutics by 32.7% in the third quarter. Prosight Management LP now owns 567,898 shares of the company’s stock valued at $650,000 after purchasing an additional 139,979 shares in the last quarter. 90.89% of the stock is owned by institutional investors and hedge funds.

Rein Therapeutics Company Profile

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.